Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovaBay Pharmaceuticals (NBY) Return on Capital Employed (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Return on Capital Employed for 15 consecutive years, with 1.78% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed rose 134.0% to 1.78% in Q3 2025 year-over-year; TTM through Sep 2025 was 1.78%, a 134.0% increase, with the full-year FY2024 number at 1.72%, down 124.0% from a year prior.
  • Return on Capital Employed was 1.78% for Q3 2025 at NovaBay Pharmaceuticals, down from 1.04% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.45% in Q3 2022 to a low of 6.44% in Q4 2024.
  • A 5-year average of 1.55% and a median of 1.04% in 2025 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: tumbled -593bps in 2024, then soared 374bps in 2025.
  • NovaBay Pharmaceuticals' Return on Capital Employed stood at 0.6% in 2021, then crashed by -58bps to 0.95% in 2022, then skyrocketed by 46bps to 0.51% in 2023, then crashed by -1159bps to 6.44% in 2024, then skyrocketed by 72bps to 1.78% in 2025.
  • Per Business Quant, the three most recent readings for NBY's Return on Capital Employed are 1.78% (Q3 2025), 1.04% (Q2 2025), and 1.73% (Q1 2025).